John Sourbeer
Stock Analyst at UBS
(0)
# 4347
Out of 5,243 analysts
46
Total ratings
41.67%
Success rate
-10.71%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
West Pharmaceutical ... | Upgrades: Buy | 350 390 | 327.93 | 18.93% | 3 | Dec 12, 2024 | |
Pacific Biosciences | Downgrades: Neutral | 2 | 1.75 | 14.29% | 3 | Nov 11, 2024 | |
Illumina | Maintains: Neutral | 133 145 | 135.94 | 6.66% | 3 | Nov 5, 2024 | |
QuidelOrtho | Upgrades: Neutral | 42 50 | 41.49 | 20.51% | 2 | Sep 19, 2024 | |
Singular Genomics Sy... | Maintains: Neutral | 12 15 | 19.68 | -23.78% | 2 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 17 | 7.49 | 126.97% | 4 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 452 480 | 336.9 | 42.48% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 7 8 | 2.74 | 173.72% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 94 102 | 59.33 | 71.92% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 58 64 | n/a | n/a | 6 | Feb 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 50 44 | 45.51 | -4.94% | 3 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 7 3 | n/a | n/a | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 50 | 15.39 | 224.89% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 68 | n/a | n/a | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 270 | 198.51 | 36.01% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 142 128 | 111.39 | 14.91% | 2 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 4 | n/a | n/a | 2 | Mar 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 22 | 22.15 | -0.68% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 23 | n/a | n/a | 1 | Feb 22, 2021 |